On 16 December, NVIDIA Corporation (NASDAQ:NVDA) shares increased 0.61% and was closed at $33.17. NVDA EPS growth in last 5 year was 62.50%. NVIDIA Corporation (NASDAQ:NVDA) year to date (YTD) performance is 68.18%.
On 10 December, NVIDIA Corporation (NASDAQ:NVDA) Facebook Inc. (NASDAQ:FB) will use NVIDIA Tesla Accelerated Computing Platform to power its upcoming next-generation computing system. This will help Facebook drive a broad range of machine-learning applications.
Smith & Nephew plc (NYSE:SNN) ended the last trading day at $32.95. Company weekly volatility is calculated as 1.22% and price to cash ratio as 167.06. Smith & Nephew plc (NYSE:SNN) showed a weekly performance of -0.24%.
Smith & Nephew plc (NYSE:SNN)‘s stock had its “buy”rating reaffirmed by stock analysts at AlphaValue in a report issued on Thursday, Marketbeat.com reports. They presently have a $21.26 price objective on the stock. AlphaValue’s price target would indicate a potential upside of 23.41% from the stock’s previous close.
On 16 December, Royale Energy Inc. (NASDAQ:ROYL) shares moved down -8.11% and was closed at $0.34. ROYL EPS growth in last 5 year was 10.20%. Royale Energy Inc. (NASDAQ:ROYL) year to date (YTD) performance is -83.89%.
Royale Energy Inc. (NASDAQ:ROYL) announced that , the Company was notified that the Nasdaq Listing Qualifications Panel (the “Panel”) has granted the Company’s request for an extension, through April 4, 2016, to evidence compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. The Company’s continued listing on Nasdaq is subject to a number of conditions, which the Company is diligently working to satisfy on a timely basis. There can be no assurance, however, that the Company will be able to do so.
Hydrogenics Corporation (NASDAQ:HYGS) shares advanced 8.02% in last trading session and ended the day at $8.62. HYGS Gross Margin is 18.20% and its has a return on assets of -18.80%. Hydrogenics Corporation (NASDAQ:HYGS) quarterly performance is -7.31%.
Hydrogenics Corporation (NASDAQ:HYGS) announced that it has successfully completed its previously announced underwritten public offering of 2,448,385 common shares (the “Offering”) at a price of $7.75 per share, which includes 319,354 common shares issued pursuant to the over-allotment option granted to the underwriters, which was exercised in full. After deducting the underwriter discount and commissions, the Company received proceeds before expenses of $17,883,922.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $1.15. Company weekly volatility is calculated as 5.54% and price to cash ratio as 3.67. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of -4.17%.
On 10 December, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced financial results for the second quarter of fiscal year (FY) 2016 ended October 31, 2015, and provided an update on its advancing clinical pipeline and other corporate developments. –Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New Clinical Trials Are Being Initiated.
Leave a Reply